Recap: Rani Therapeutics Hldgs Q4 Earnings
Portfolio Pulse from Benzinga Insights
Rani Therapeutics Holdings (NASDAQ:RANI) reported Q4 earnings, beating estimates with an EPS of $-0.27 against an expected $-0.31. However, revenue remained unchanged from the previous year. This follows a pattern from the last quarter where beating EPS estimates led to a 3% drop in share price the next day.
March 20, 2024 | 8:25 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rani Therapeutics Holdings reported a Q4 EPS of $-0.27, surpassing the expected $-0.31, with unchanged revenue from the previous year. Historically, beating EPS estimates led to a share price drop.
Despite beating EPS estimates, RANI's historical performance indicates a potential short-term negative impact on its share price, as seen in the last quarter where a similar earnings beat was followed by a 3% drop in share price. The unchanged revenue could also contribute to investor skepticism.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100